Provider: Wright Reports
Basilea Pharmaceutica AG: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Basilea Pharmaceutica AG Appoints Ronald Scott As CEO To Succeed Anthony Man
Basilea Pharmaceutica AG announced that it has promoted Ronald Scott, previously Chief Operating Officer, to Chief Executive Officer (CEO) effective January 1, 2013 to succeed Anthony Man, who has decided for personal reasons to leave the Company as of December 31, 2012.
Latest Developments for Basilea Pharmaceutica AG
- Basilea Pharmaceutica AG confirms FY 2014 guidance
- Basilea Pharmaceutica AG submits isavuconazole European Marketing Authorization Application for the treatment of invasive mold infections
- Basilea Pharmaceutica AG announces isavuconazole received QIDP designation from U.S. FDA
- Basilea Pharmaceutica AG Isavuconazole receives orphan drug designations in Europe
Latest Key Developments in Biotechnology
- Zealand Pharma A/S maintains FY 2014 financial guidance
- BioSpecifics Technologies Corp announces positive data from Phase 2a study of CCH for treatment of Cellulite
- OncoGenex Pharmaceuticals Inc announces update on phase 3 ENSPIRIT trial evaluating Custirsen in advanced non-small cell lung cancer
- Galena Biopharma appoints Mark W. Schwartz, Ph.D., as President and Chief Executive Officer
- Share this
- Digg this